Categories
Nevin Manimala Statistics

Uncovering barriers to screening for distress in patients with cancer via machine learning

J Acad Consult Liaison Psychiatry. 2021 Aug 23:S2667-2960(21)00144-0. doi: 10.1016/j.jaclp.2021.08.004. Online ahead of print.

ABSTRACT

PURPOSE: Psychological distress and manifest mental disorders are overlooked in 30 to 50% of patients with cancer. Accordingly, international cancer treatment guidelines recommend routine screening for distress in order to provide psychological support to those in need. Yet, institutional and patient related factors continue to hinder implementation. This study aims to investigate factors, which are associated with no screening for distress in cancer patients.

METHODS: Using machine learning, factors associated with lack of distress screening were explored in 6,491 patients with cancer between 2011 and 2019 at a large cancer treatment center. Parameters were hierarchically ordered based on statistical relevance. Nested resampling and cross validation were performed to avoid overfitting and to comply with assumptions for machine learning approaches.

RESULTS: Patients unlikely to be screened were not discussed at a tumor board, had inpatient treatment of less than 28 days, did not consult with a psychiatrist or clinical psychologist, had no (primary) nervous system cancer, no head and neck cancer, and did have breast or skin cancer. The final validated model was optimized to maximize sensitivity at 83.9% and achieved a balanced accuracy of 68.9, AUC of 0.80, and specificity of 53.9%.

CONCLUSION: Findings of this study may be relevant to stakeholders at both a clinical and institutional level in order to optimize distress screening rates.

PMID:34438098 | DOI:10.1016/j.jaclp.2021.08.004

Categories
Nevin Manimala Statistics

The Clinical Use of Serum Biomarkers in Traumatic Brain Injury: A Systematic Review Stratified by Injury Severity

World Neurosurg. 2021 Aug 23:S1878-8750(21)01243-2. doi: 10.1016/j.wneu.2021.08.073. Online ahead of print.

ABSTRACT

BACKGROUND: Serum biomarkers have gained significant popularity as an adjunctive measure in the evaluation and prognostication of traumatic brain injury (TBI). However, a concise and clinically oriented report of the major markers in function of TBI severity is lacking.

OBJECTIVE: This systematic review aims to report current data on the diagnostic and prognostic utility of blood-based biomarkers across the spectrum of TBI.

METHODS: A literature search of the PubMed/Medline electronic database was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We excluded systematic reviews and meta-analyses that did not provide novel data. The American College of Cardiology/American Heart Association criteria were used to assess levels of evidence.

RESULTS: An initial 1463 studies were identified. 115 full-text articles reporting on 94 distinct biomarkers met the inclusion criteria. Glasgow Coma Scale scores, computed tomography/magnetic resonance imaging abnormalities, and injury severity scores were the most used clinical diagnostic variables. Glasgow Outcome Scores, 1, 3, and 6-month mortality were the most used clinical prognostic variables. Several biomarkers significantly correlated with these variables and had statistically significant different levels in TBI subjects when compared to healthy, orthopedic, and polytrauma controls. The biomarkers also displayed significant variability across mild, moderate, and severe TBI categories, as well as in concussion cases.

CONCLUSION: This review summarizes existing high-quality evidence that supports the use of severity-specific biomarkers in the diagnostic and prognostic evaluation of TBI. This data can be used as a launching platform for the validation of upcoming clinical studies.

PMID:34438102 | DOI:10.1016/j.wneu.2021.08.073

Categories
Nevin Manimala Statistics

SPARC positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double/triple hit status

Ann Oncol. 2021 Aug 23:S0923-7534(21)04275-7. doi: 10.1016/j.annonc.2021.08.1991. Online ahead of print.

ABSTRACT

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with respect to outcome. Features of the tumor microenvironment are associated with prognosis when assessed by gene expression profiling. However, it is uncertain whether assessment of the microenvironment can add prognostic information to the most relevant and clinically well-established molecular subgroups when analyzed by immunohistochemistry.

PATIENTS AND METHODS: We performed a histopathologic of biomarkers related to tumor microenvironment in a very large cohort (n=455) of DLBCL treated in prospective trials and correlated with clinic-pathologic and molecular data, including chromosomal rearrangements and gene expression profiles for cell-of-origin and tumor microenvironment.

RESULTS: The content of PD1+, FoxP3+ and CD8+, as well as vessel density, was not associated with outcome. However, we found a low content of CD68+ macrophages to be associated with inferior progression-free (PFS) and overall survival (OS) (p=0.023 and p=0.040, respectively) both at univariable and multivariable analysis, adjusted for the factors of the international prognostic index (IPI), MYC break and BCL2/MYC and BCL6/MYC double hit status. The subgroup of PDL1+ macrophages was not associated with survival. Instead, Secreted Protein Acidic And Cysteine Rich (SPARC)-positive macrophages were identified as the subtype of macrophages most associated with survival. SPARC-positive macrophages and stromal cells directly correlated with favorable PFS and OS (both, p[log rank] <0.001, p[trend]<0.001). The association of SPARC with prognosis was independent of the factors of the IPI, MYC double/triple hit status, Bcl2/c-myc double expression, cell of origin subtype and a recently published gene expression signature (LAMIS).

CONCLUSIONS: SPARC expression in the tumor microenvironment detected by a single immunohistochemical staining with fair-to-good inter-observer reproducibility is a powerful prognostic parameter. Thus, SPARC expression is a strong candidate for risk assessment in DLBCL in daily practice.

PMID:34438040 | DOI:10.1016/j.annonc.2021.08.1991

Categories
Nevin Manimala Statistics

Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in people living with HIV-1

Clin Microbiol Infect. 2021 Aug 23:S1198-743X(21)00423-7. doi: 10.1016/j.cmi.2021.07.031. Online ahead of print.

ABSTRACT

OBJECTIVES: The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine in people living with HIV-1 (PLWH) are unknown. We thus aimed to assess the immunogenicity and safety of this vaccine in PLWH.

METHODS: In this prospective open study, we enrolled 143 PLWH, aged ≥18 years, who attended our clinic and 261 immunocompetent health care workers (HCWs). SARS-CoV-2 receptor binding domain (RBD) IgG and neutralizing antibodies were measured. Adverse events, viral load and CD4 cell counts were monitored.

RESULTS: At a median of 18 days (IQR 14-21) after the second dose, anti-RBD IgG was positive in 139/141 (98%) PLWH. Among HCWs, 258/261 (98.9%) developed anti-RBD IgG at a median of 26 (IQR 24-27) days after the second dose. Following the second dose, immune sera neutralized SARS-CoV-2 pseudo-virus in 97% and 98% of PLWH and HCW, respectively. Adverse events were reported in 60% of PLWH, mainly pain at the injection site, fatigue, and headache. AIDS-related adverse events were not reported. HIV viral load increased in 3/143 (2%) patients from < 40 copies/mL to ≤ 100 copies/mL. CD4+ T cell count decreased from a geometric mean of 700 (95% CI 648-757) cells per μL to 633.8 (95% CI 588-683) cells per μL (P<0.01).

CONCLUSIONS: BNT162b2 mRNA vaccine appears immunogenic and safe in PLWH who are on ART with unsuppressed CD4 count and suppressed viral load.

PMID:34438069 | DOI:10.1016/j.cmi.2021.07.031

Categories
Nevin Manimala Statistics

A randomized, placebo-controlled, double-blind study on the effects of SZL on patients with mild to moderate depressive disorder with comparison to fluoxetine

J Ethnopharmacol. 2021 Aug 23:114549. doi: 10.1016/j.jep.2021.114549. Online ahead of print.

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Kaixinsan (KXS) decoction, as an herbal formula, was used to treat the diseases, such as insomnia, amnesia, emotional disorders in ancient china. It has been demonstrated to be active in various animal models resembling human depression with multitarget effects. However, effective verification on the clinical application of KXS is still lacking. Supplements in this knowledge field are urgently needed.

AIM OF THE STUDY: This very first study evaluated the efficacy and tolerability of ShenZhiLing (SZL) tablets (KXS preparation), compared with fluoxetine (FLX, positive comparator), in patients with mild to moderate depressive disorder.

MATERIALS AND METHODS: In this randomized, double-blind, parallel-group study, 156 patients with mild to moderate depression without taken any antidepressants in the past 6 months or 4 continuous weeks were randomized to receive either 3.2g/d SZL plus 20mg/d FLX placebo (SZL group) or 20mg/d FLX plus 3.2g/d SZL placebo (FLX group), for 8 weeks. Their clinical presentations and some metabolic indexes were assessed during the 8 weeks’ visiting period.

RESULTS: Patients in SZL group showed a statistically significant improvement after 8 weeks of treatment in HAM-D17 score (18.79±2.09 to 4.43±4.71, p<0.001) and self-rating depression scale (SDS) score (58.49±8.89 to 39.84±12.09, p<0.001), but not in N-back total respond time (1145.55±608.26 to 1128.47±387.49, p>0.05). In addition, no significant difference at 8 weeks of treatment was found between SZL and FLX groups in SDS score (39.84±12.09 vs. 36.63±12.44) and N-back respond time (1128.47±387.49 vs. 1089.43±352.08) as well as reduction of HAM-D17 score (14.79±4.88 vs. 15.24±4.29) (p>0.05 for all). However, the serum APOB, APOC3 and ALB levels and LDL-C/HDL-C ratio decreased significantly in patients after SZL treatment, while only APOB/APOA1 ratio decreased significantly in FLX group. Other metabolic indexes did not alter significantly after treated with SZL or FLX.

CONCLUSION: The efficacy and safety profile of SZL are comparable to that of fluoxetine in patients with mild to moderate depression. The beneficial effect of SZL is probably associated with improvement of lipid metabolic balance.

PMID:34438029 | DOI:10.1016/j.jep.2021.114549

Categories
Nevin Manimala Statistics

Evaluation of a Proactive Hiring Model to Achieve Workforce Stability in the Intensive Care Unit

J Nurs Manag. 2021 Aug 26. doi: 10.1111/jonm.13465. Online ahead of print.

ABSTRACT

AIM: The purpose was to evaluate an innovative Prospective Hiring Equation to determine registered nurse hiring needs.

BACKGROUND: The American Organization for Nursing Leadership identifies human resource management as a competency for nurse managers, yet calculations to determine when and how many registered nurses to hire are not readily available.

METHODS: We implemented an educational intervention to teach nurse mangers the Prospective Hiring Equation. We evaluated the processes (adoption, confidence) and outcomes (vacancy rates) using a pre/post evaluation design in a single cohort of nurse managers (n=9). We used a statistical process control chart to depict mean differences in vacancy rate at baseline and 6-months post-implementation.

RESULTS: Participants (n=9) were on average 43 years’ old, female, and had 2.94 (SD=2.66) years’ of nurse manager experience. Following implementation of the intervention, the combined vacancy rates of the intensive care units improved by 11.8% (SD=7), and use of agency nurses decreased by 42.5% (pre-median=7.2, interquartile ratio=3.6, 10.8; post-median=1.8, interquartile ratio 0.9, 8.55).

CONCLUSIONS: The Prospective Hiring Equation may be a useful tool to improve nurse managers human resource management competencies.

IMPLICATIONS FOR NURSING MANAGEMENT: The Prospective Hiring Equation may help nurse managers improve accuracy when evaluating hiring needs.

PMID:34437739 | DOI:10.1111/jonm.13465

Categories
Nevin Manimala Statistics

Reply to letter

Arthritis Care Res (Hoboken). 2021 Aug 26. doi: 10.1002/acr.24771. Online ahead of print.

ABSTRACT

We thank Li et al for their commentary on our recently published paper “Mortality in Ankylosing Spondylitis According to Treatment: A Nationwide Retrospective Cohort Study of 5900 Patients from Israel” (1). Their major concern was regarding the findings which demonstrated no excess mortality in ankylosing-spondylitis (AS) patients treated with TNF-inhibitors (TNFi).

PMID:34437772 | DOI:10.1002/acr.24771

Categories
Nevin Manimala Statistics

The Acute Effects of Ischemic Preconditioning on Power and Sprint Performance

S D Med. 2021 May;74(5):210-219.

ABSTRACT

INTRODUCTION: Ischemic preconditioning (IPC) has been shown to induce positive effects on skeletal muscle resulting in enhanced physical performance. Data display that IPC positively impacts both aerobic and anaerobic performance. However, there is inconclusive data exemplifying IPC’s effects on power and sprint performance. We hypothesized 15 minutes of bilateral lower limb IPC, applied 25-45 minutes prior to power and sprint activity, would enhance power and sprint performance.

METHODS: Using a randomized crossover design, 14 NCAA Division II athletes received IPC (100 percent occlusion) and sham (50 mmHg) treatments followed by either a 0 minute or a 20 minute rest. A Delfi Personalized Tourniquet System (PTS) for blood flow restriction with an internal doppler radar was used to occlude blood flow to the lower extremities. Followed by IPC treatment, power and sprint performance was assessed using a vertical jump, reactive strength index (RSI), broad jump, flying 10m dash, and pro-agility. Each of the fourteen subjects in the experimental group received all four protocols.

RESULTS: Using an ANOVA, no statistical significance was found between the type of treatment (i.e., sham 0 min, sham 20 min, IPC 0 min, IPC 20 min) and the performance tests: vertical jump (p=0.97), RSI (p=0.73), broad jump (p=0.98), flying 10m dash (p=0.99), and pro-agility (p=0.90). In addition, no statistical significance was found between the order of treatments and the performance tests (p=0.97).

CONCLUSION: Despite previous research suggesting IPC enhances anaerobic and anaerobic performance, the current results indicate IPC doesn’t significantly enhance power and sprint performance in highly trained athletes.

PMID:34437779

Categories
Nevin Manimala Statistics

Simultaneous feature selection and outlier detection with optimality guarantees

Biometrics. 2021 Aug 26. doi: 10.1111/biom.13553. Online ahead of print.

ABSTRACT

Biomedical research is increasingly data rich, with studies comprising ever growing numbers of features. The larger a study, the higher the likelihood that a substantial portion of the features may be redundant and/or contain contamination (outlying values). This poses serious challenges, which are exacerbated in cases where the sample sizes are relatively small. Effective and efficient approaches to perform sparse estimation in the presence of outliers are critical for these studies, and have received considerable attention in the last decade. We contribute to this area considering high-dimensional regressions contaminated by multiple mean-shift outliers affecting both the response and the design matrix. We develop a general framework and use mixed-integer programming to simultaneously perform feature selection and outlier detection with provably optimal guarantees. We prove theoretical properties for our approach, i.e., a necessary and sufficient condition for the robustly strong oracle property, where the number of features can increase exponentially with the sample size; the optimal estimation of parameters; and the breakdown point of the resulting estimates. Moreover, we provide computationally efficient procedures to tune integer constraints and warm-start the algorithm. We show the superior performance of our proposal compared to existing heuristic methods through simulations and use it to study the relationships between childhood obesity and the human microbiome. This article is protected by copyright. All rights reserved.

PMID:34437713 | DOI:10.1111/biom.13553

Categories
Nevin Manimala Statistics

Fornix-based versus limbal-based conjunctival trabeculectomy flaps for glaucoma

Cochrane Database Syst Rev. 2021 Aug 26;8:CD009380. doi: 10.1002/14651858.CD009380.pub3.

ABSTRACT

BACKGROUND: Glaucoma is one of the leading largely preventable causes of blindness in the world. It is usually addressed first medically with topical intraocular pressure-lowering drops or by laser trabeculoplasty. In cases where such treatment fails, glaucoma-filtering surgery such as trabeculectomy, is commonly considered. Surgeons can differ in their technique when performing trabeculectomy, for example, the choice of the type of the conjunctival flap (fornix- or limbal-based). In a fornix-based flap, the surgical wound is performed at the corneal limbus; while in a limbal-based flap, the incision is further away. Many studies in the literature compare fornix- and limbal-based trabeculectomy with respect to outcomes and complications.

OBJECTIVES: To assess the comparative effectiveness of fornix- versus limbal-based conjunctival flaps in trabeculectomy for adult glaucoma, with a specific focus on intraocular pressure (IOP) control and complication rates (adverse effects).

SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; which contains the Cochrane Eyes and Vision Trials Register; 2021, Issue 3); Ovid MEDLINE; Ovid Embase; the ISRCTN registry; ClinicalTrials.gov and the WHO ICTRP. The date of the search was 23 March 2021. There were no restrictions to language or year of publication.

SELECTION CRITERIA: We included RCTs comparing the benefits and complications of fornix- versus limbal-based trabeculectomy for glaucoma, irrespective of glaucoma type, publication status, and language. We excluded studies on children less than 18 years of age, since wound healing is different in this age group and the rate of bleb scarring postoperatively is high.

DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as per Cochrane criteria. MAIN RESULTS: We did not identify any new eligible studies for this review update. As presented in the original review, we included six trials with a total of 361 participants. Two studies were conducted in the USA and one each in Germany, Greece, India, and Saudi Arabia. The participants of four trials had open-angle glaucoma; one study included participants with primary open-angle or primary closed-angle glaucoma, and one study did not specify the type of glaucoma. Three studies used a combined procedure (phacotrabeculectomy). Trabeculectomy with mitomycin C (MMC) was performed in four studies, and trabeculectomy with 5-fluorouracil (5-FU) was performed in only one study. None of the included trials reported trabeculectomy failure at 24 months. Only one trial reported the failure rate of trabeculectomy as a late complication. Failure was higher among participants randomised to the limbal-based surgery: 1/50 eyes failed trabeculectomy in the fornix group compared with 3/50 in the limbal group (Peto odds ratio 0.36, 95% confidence interval (CI) 0.05 to 2.61)); therefore we are very uncertain as to the relative effect of the two procedures on failure rate. Four studies including 252 participants provided measures of mean IOP at 12 months. In the fornix-based surgeries, mean IOP ranged from 12.5 to 15.5 mmHg and similar results were noted in limbal-based surgeries with mean IOP ranging from 11.7 to 15.1 mmHg without significant difference. Mean difference was 0.44 mmHg (95% CI -0.45 to 1.33; 247 eyes) and 0.86 mmHg, (95% CI -0.52 to 2.24; 139 eyes) at 12 and 24 months of follow-up, respectively. Neither of these pooled analyses showed a statistically significant difference in IOP between groups (moderate certainty evidence). One trial reported number of anti-glaucoma medications at 24 months of follow-up with no difference noted between surgical groups. However, three trials reported the mean number of anti-glaucoma medications at 12 months of follow-up without significant difference in the mean number of postoperative IOP-lowering medications between the two surgical techniques. Mean difference was 0.02, (95% CI -0.15 to 0.19) at 12 months of follow-up (high certainty evidence). Because of the small numbers of events and total participants, the risk of many reported adverse events was uncertain and those that were found to be statistically significant may have been due to chance. For risk of bias assessment: although all six trials were randomised selection bias was mostly unclear, with unclear random sequence generation in four of the six studies and unclear allocation concealment in five of the six studies. Attrition bias was encountered in only one trial which also suffered from reporting bias. All other trials had an unclear risk of reporting bias as there was no access to study protocols. All included trials were judged to have high risk of detection bias due to lack of masking of the outcomes. Trabeculectomy is quite a standard procedure and unlikely to induce bias due to surgeon ‘performance’, hence performance bias was not evaluated.

AUTHORS’ CONCLUSIONS: The main result of this review was that there was uncertainty as to the difference between fornix- and limbal-based trabeculectomy surgeries due to the small number of events and confidence intervals that cross the null. This also applied to postoperative complications, but without any impact on long-term failure rate between the two surgical techniques.

PMID:34437715 | DOI:10.1002/14651858.CD009380.pub3